Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

LBA1 Dynamic circulating tumor DNA methylation monitoring guiding postoperative surveillance in non-metastatic colorectal cancer: Interim analysis of FIND trial

Cumulative recurrence rates did not differ (P=0.671 ITT). ctDNA-guided surveillance increased the proportion of recurrent patients who received curative-intent therapy (50.0% vs 22.6%; relative risk 2.214, 95% CI 1.060-4.780; P=0.034), the trial's primary endpoint. This is an interim analysis.

ESMO Gastrointestinal Cancers Congress 2025